ClinicalTrials.gg
CompletedNCT00656474Updated Oct 28, 2021Results posted

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

A Phase 1/2 interventional study of Placebo gel and GLYC-101 gel (1.0 %) in Wounds, sponsored by TR Therapeutics. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by TR Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

Read the detailed description

The proposed pilot-study will document feasibility, safety and efficacy of topically applied Glucoprime gel (GLYC-101 gel 1.0 %) in promoting wound healing in healthy volunteer subjects undergoing retro-auricular Carbon Dioxide Laser Skin Resurfacing (CO2 LSR). The study will observe the effects of the topical agent over the course of 1 month following the treatment. as a preparation for study GLYC-101-1b (Double-blind, randomized, placebo-controlled Phase 2 Pilot Study to investigate the safety and efficacy of 1.0 % topically applied GLYC 101 compared to placebo, in patients undergoing Carbon Dioxide Laser Skin Resurfacing).

02

Conditions studied

  • Wounds

Keywords

  • burn wounds
  • wound healing
03

In context

Wounds and Injuries

2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's enrollment of 12 is below the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

TR Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting all of the following criteria will be considered for admission to the study:

  • Patients giving for retro-auricular laser ablation between 25 and 55 years old.
  • Retro-auricular area is free of any irritation, scars or dermatologic conditions which might interfere with the study.
  • Willing and able to participate in the study and follow all study directions.
  • Able to read, understand and sign the consent form.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test.
  • Systemic or cutaneous disease that may interfere with the study results.
  • Presence of irritation or dermatologic skin conditions in the retro-auricular area.
  • Known allergies to materials within the test formulations.
  • Systemic or cutaneous therapy with medication that impacts wound healing (, immune modulators, immune suppressants).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    1

    GLYC-101 Active Retro-auricular Site (1 per participant)

    Drug: GLYC-101 gel (1.0 %)

  • Placebo comparator
    2 Comparator

    Placebo Retro-auricular Site (1 per participant) This arm undergoes laser ablation with subsequent Placebo gel administration

    Drug: Placebo gel

Interventions

  • DrugPlacebo gel

    Administration of Placebo gel on Day 1, 3 and 5 post ablation.

  • Administration on Day 1, 3 and 5 post laser ablation.

06

What researchers measure

Primary outcomes

  1. Time to Complete Wound Closure (Epithelialization)

    Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.

    Time frame: Over the course of 1 month following the initial treatment.

Secondary outcomes

  1. Percentage of Wound Epithelialized

    The percentage of wound epithelialized was assessed at Day 15 post laser ablation.

    Time frame: Day 15 post laser ablation.

07

Results

Posted Jul 25, 2011

Participant flow

Recruitment occurred in March 2008 at a single site, Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States, 90210.

Participant flow — Overall Study
MilestoneGLYC-101 and Placebo
Started12
Completed11
Not completed1
Withdrew: Other reason1

Outcome measures

PrimaryTime to Complete Wound Closure (Epithelialization)

Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.

Time frame:
Over the course of 1 month following the initial treatment.
Reported as:
Median · days
Time to Complete Wound Closure (Epithelialization)
daysGLYC-101 Active Retro-auricular Site (1 Per Participant)Placebo Retro-auricular Site (1 Per Participant)
Time to Complete Wound Closure (Epithelialization)15 (15 to 15)15 (15 to 15)
SecondaryPercentage of Wound Epithelialized

The percentage of wound epithelialized was assessed at Day 15 post laser ablation.

Time frame:
Day 15 post laser ablation.
Reported as:
Number · percent
Percentage of Wound Epithelialized
percentGLYC-101 Active Retro-auricular Site (1 Per Participant)Placebo Retro-auricular Site (1 Per Participant)
Percentage of Wound Epithelialized100100

Adverse events

Collected over Adverse Events (AEs) were collected over the course of 1 month.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GLYC-101 and Placebo—0/12 (0%)12/12 (100%)
Most frequent other events
Most frequent other events
EventGLYC-101 and Placebo
ErythemaSkin and subcutaneous tissue disorders12/12
HeadacheNervous system disorders11/12
Ear PruritusEar and labyrinth disorders3/12
GranulomaGeneral disorders1/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GLYC-101 and Placebo
<=18 years0
Between 18 and 65 years12
>=65 years0
Age, Continuous
Age, Continuous(years)GLYC-101 and Placebo
Mean50.3 ± 8.93
Sex: Female, Male
Sex: Female, Male(Participants)GLYC-101 and Placebo
Female12
Male0
Region of Enrollment
Region of Enrollment(participants)GLYC-101 and Placebo
United States12
08

Study locations

1 site
  • CLINICAL TESTING CENTER of BEVERLY HILLS
    Beverly Hills, California 90210, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Apr 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2008
First posted
Apr 11, 2008
Start
Mar 2008
Primary completionActual
Apr 2008
CompletionActual
Aug 2008
Results first posted
Jul 25, 2011
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00656474
Lead sponsor
TR Therapeutics
Responsible party
Sponsor
First posted
Apr 11, 2008
Start date
Mar 2008
Primary completion
Apr 2008
Completion
Aug 2008
Results posted
Jul 25, 2011
Last update
Oct 28, 2021

Study contacts

John Joseph, MD
principal investigator · CLINICAL TESTING CENTER of BEVERLY HILLS
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yeast .beta.-d-glucan

Start the discussion